

**Patient Group Direction**

**Administration of Sando K Tablets**

By Registered Nurses employed by South Staffordshire & Shropshire Healthcare  
Foundation NHS Trust

**This Patient Group Direction for use in South Staffordshire & Shropshire  
Healthcare NHS Foundation Trust and is authorised by:**

Position of Signatory	Name	Signed	Date
Medical Director	Dr Abid Khan		
Chief Pharmacist	Cathy Riley		
Director of Quality & Clinical Performance	Theresa Moyes		
Director of Nursing	Alison Bussey		

**The named below, being employees of  
South Staffordshire & Shropshire Healthcare NHS Foundation Trust  
are authorised to administer Sando K  
under this Patient Group Direction**

Name	Job Title	Signed	Date

**This Patient Group Direction is operational from Feb 2017. Review date:  
January 2019. Expires on 30th March 2019**

**This PGD replaces PGD1314**

## **Professional Responsibility**

**All registered nurses being employees of South Staffordshire & Shropshire HealthCare NHS Foundation Trust, and working on Kinver ward, are authorised to administer Sando K as specified under this Patient Group direction following demonstration of the competencies below;**

### **Professional Responsibility / competencies**

1. All Registered health care professionals who have completed training in correcting biochemical abnormalities through nutritional supplementation within the last 2 years.
2. All nurses will have received training in the management and treatment of anaphylactic shock on an annual basis
3. Each nurse will keep a record in their professional portfolio of the updates attended during every 12 month period – This information will also form part of the team's annual training plan
4. The nurse will have due regard for the NMC Code of Conduct, Scope of Professional Practice and Standards for Medicines Management (Nursing & Midwifery Council)
5. Undertaken appropriate training and possess the competencies for working under PGDs for the supply and administration of medicines
6. All registered nurses details and signature must be entered on the PGD
7. Following administration a record of the date, and dose of the medicine should be recorded in the clients records, and within the As Required section of the medicine card, with PGD Number being inserted in place of prescriber's instructions

**For full product information, always refer to the latest SPC (Summary of Product Characteristics).**

<b>Administration of</b>	Sando K effervescent tablets
<b>Legal Classification</b>	P
<b>Black Triangle?</b>	No
<b>Type</b>	Tablets/effervescent
<b>Storage</b>	Locked cupboard at room temperature
<b>Condition to be treated</b>	Hypokalaemia
<b>Inclusion Criteria</b>	Adults 16 years and over Blood potassium 2.5 – 3.5 mmol
<b>Exclusion Criteria</b>	<ul style="list-style-type: none"> <li>• Blood potassium &lt;2.5 – needs medical admission for intravenous replacement and cardiac monitoring</li> <li>• Pregnancy and lactation</li> <li>• Severe renal impairment (GFR less than 10 ml/minute; serum creatinine &gt; 700 micromol/l) with oliguria (decreased urine production &lt;400ml/ 24h))</li> <li>• Inadequately treated Addison's disease</li> </ul>
<b>Action if excluded or patient declines</b>	<p><b>Declined:</b> Record refusal in care record – contact duty doctor</p> <p><b>Excluded:</b> Contact duty doctor</p>
<b>Reasons for seeking further advice from doctor</b>	If in doubt or If potassium levels do not come into normal range 3.5 – 5.0 within 48 hours
<b>Administration Route</b>	Oral, after dissolution in water, and with food if preferred
<b>Dose</b>	2 tablets three times daily
<b>Administration Schedule</b>	<p>2 tablets 6-8 hourly three times a day <u>for 48 hours</u></p> <ul style="list-style-type: none"> <li>• max dose in 24 hours (6 tablets)</li> <li>• Total dose to be administered via PGD – no more than 12 tablets/48 hour treatment</li> <li>• Monitor biochemistry daily to include calcium, phosphate, potassium and magnesium</li> </ul>
<b>Warnings/Adverse</b>	Abdominal discomfort, diarrhoea, nausea and

<b>Reactions</b>	vomiting may occur.  <b>For full details see Summary of Product Characteristics</b>
<b>Advice/Management of Adverse Reactions &amp; Follow-up Action</b>	If there are signs of gastric irritancy, then give subsequent doses with or after food. If patient experiences severe symptoms, contact the duty doctor.  <b>Anaphylaxis Emergency Treatment</b> See PGD for the Administration of Adrenaline (Epinephrine) 1:1000.
<b>Use in pregnancy and lactation</b>	<u>Pregnancy-</u> excluded, refer to duty doctor <u>Lactation:</u> excluded, refer to duty doctor
<b>Records</b>	Use of medications via a PGD will be clearly documented within the Integrated Care Record.  <u>and</u> the administration also recorded in the medicine card/electronic prescribing & medicines administration record, with the PGD Number recorded as authorisation.